We've been waiting for 5 years for this one to move forward.
Semaglutide has 2
phase 3 trials about to enroll with ~3700
The AD treatment landscape is opening up everywhere.
[This is for liraglutide]
"Oh, and there is (a) savings card, pay no more than $25 out of pocket for a prescription.https://www.victoza.com/get-started-usi
A near generic for Alzheimer's with a coupon and only a $25 copay?
Life is good. Life is very good.
There is just so much money out there for pharma to grab and at the same time this will be such a huge win for the dementia community.
Oh, yeah; semaglutide in the AD trials will be an oral (not injectable) formulation.
So much is happening in AD treatment now. 2021-2022 is the time that everything changes in AD therapy. viewtopic.php?f=4&t=2204&p=80556#p80556
Only clouds I am seeing here is that they do not appear to have included tau imaging or even APOE genotyping.
Given the current knowledge base 3,700
patients really might not be even needed to demonstrate efficacy.
With tau selection and perhaps selection on covariates you might get to down ~50 in the treatment arm.
Why not do this right and have the answer for us in 50 weeks and not 5 years?
To learn from the experience with aducan, perhaps they could use an adaptive selection mechanism.
Once they achieved convincing evidence for the most favored demographic, the FDA could grant that demographic
approval. The trial could continue along with rolling approvals. AD is a somewhat heterogeneous illness. Why not
simply acknowledge that and give the advantage to the patient community? Averaging everything out makes it more difficult
to rapidly identify the super-responders.
Not completely sure if this relates to aducan, though the whole point is that as soon as you remove the driver of the pathology then other add-ons such as sema could act as amplifiers. Once we have aducan approved then they could start doing the combinations trials. However, I am not entirely clear on this point. If you remove the upstream AD drivers of neuropathology --i.e., amyloid and tau -- would their actually be anything left to treat? Doesn't everything else largely happen downstream?